Xemperia

1. Executive Summary (Confidence: High)

Xemperia represents the "cutting-edge" of the longevity biotech sector, focusing on the early detection of mortality drivers. Founded in December 2023 by Dr. Sarah Cattin and Prof. Curzio Rüegg, the company is the culmination of 25 years of research into the tumor microenvironment and immune response. Their proprietary technology uses PCR to analyze biomarkers in blood leukocytes that are "reprogrammed" by the presence of a tumor, even at the millimeter scale. With an accuracy rate of 99-100% in initial validation studies, Xemperia is preparing for large-scale clinical trials and aims for a market entry by 2028-2029. The company has already gained significant traction in the Swiss startup ecosystem, winning the IFF First Prize and the Ypsomed Innovation Award.